Treating NASH

There is a need for specific drugs to treat NASH. Lifestyles are rarely enough and for patients with advanced conditions this will not be sufficient. Several drugs with different mechanisms of action are in development to treat NASH. They are currently available only via protocols but this will change in the next few years. The challenge then will be to personalize the treatment.

Farnesoid X nuclear receptor ligand obeticholic acid

For noncirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Neuschwander-Tetri BA. et al. Lancet. 2015 Mar 14; 385(9972): 956–965.

Read in full >

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN)

A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic steatosis, concentrations of liver enzymes, and insulin resistance in murine models […]

Read in full >

Elafibranor

An agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Ratziu V et al. Gastroenterology. 2016 May;150(5):1147-1159

Read in full >

Trial of Cenicriviroc

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Friedman SL et al. Hepatology. 2018 May;67(5):1754-1767. doi: 10.1002/hep.29477. Epub 2018 Jan […]

Read in full >

Improvements in histologic features and diagnosis

Associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis clinical research network treatment trials. Brunt EM et al. Hepatology. 2019 Aug;70(2):522-531

Read in full >

Emerging medical therapies for NAFLD and for alcoholic hepatitis.

Non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) are currently the two most common liver diseases in the world. Alcoholic hepatitis (AH), a unique […]

Read in full >

AASLD/EASL joint workshop

Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. Rinella ME  et al. J Hepatol. 2019 Jul 9

Read in full >

The Natural History of Advanced Fibrosis Due to NASH

Progression of nonalcoholic steatohepatitis (NASH) is incompletely characterized. We analyzed data on longitudinal changes in liver histology, hepatic venous pressure gradient (HVPG), and serum markers […]

Read in full >